Skip to content
Back to recalls
Drug FDA Class II Ongoing cGMP deviation

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323

MXBBB Published Jan 1, 2025

Risk level

Class II

May cause a temporary or reversible health problem; slight chance of serious harm.

Severity score 50/100

What should you do?

  • Check whether you have this product, using the lot codes, UPCs, and dates listed below.
  • Do not eat, serve, or sell the affected product.
  • Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
  • Contact MXBBB or your place of purchase with questions, and see the source record below for full details.
Reason for recall

cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.

Hazards

Undeclared Diclofenac · primaryUndeclared Omeprazole

Affected products (1)

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323

321 bottles

Code info: Lot#: 24183, Exp 07/01/28

Affected areas

Product was sold via Amazon Marketplace.

Timeline

  1. Initiated
    Nov 14, 2024
  2. Published
    Jan 1, 2025
Recall number
D-0166-2025
Agency
U.S. Food and Drug Administration
Country
US
Source data (openFDA JSON) About FDA enforcement reports

FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.